{"id":"https://openalex.org/W7161753686","doi":"https://doi.org/10.1016/j.jconrel.2026.115038","title":"Nanomedicines from the patient perspective \u2013 30 years after PEGylated liposomal doxorubicin","display_name":"Nanomedicines from the patient perspective \u2013 30 years after PEGylated liposomal doxorubicin","publication_year":2026,"publication_date":"2026-05-20","ids":{"openalex":"https://openalex.org/W7161753686","doi":"https://doi.org/10.1016/j.jconrel.2026.115038","pmid":"https://pubmed.ncbi.nlm.nih.gov/42167367"},"language":"en","primary_location":{"id":"doi:10.1016/j.jconrel.2026.115038","doi":"https://doi.org/10.1016/j.jconrel.2026.115038","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jconrel.2026.115038","pdf_url":null,"source":{"id":"https://openalex.org/S161954266","display_name":"Journal of Controlled Release","issn_l":"0168-3659","issn":["0168-3659","1873-4995"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Controlled Release","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035592184","display_name":"Lucy Wang","orcid":"https://orcid.org/0000-0002-9916-2733","observed_orcids":["https://orcid.org/0000-0002-9916-2733"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Lucy Wang","raw_affiliation_strings":["Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada. Electronic address: lucille.wang@mail.utoronto.ca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada. Electronic address: lucille.wang@mail.utoronto.ca","institution_ids":["https://openalex.org/I185261750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136217504","display_name":"Sandeep Sehdev","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I153718931","display_name":"University of Ottawa","ror":"https://ror.org/03c4mmv16","country_code":"CA","type":"education","lineage":["https://openalex.org/I153718931"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Sandeep Sehdev","raw_affiliation_strings":["Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada","institution_ids":["https://openalex.org/I153718931"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136601053","display_name":"Alvina Nadeem","orcid":"https://orcid.org/0009-0009-8512-1437","observed_orcids":["https://orcid.org/0009-0009-8512-1437"]},"institutions":[{"id":"https://openalex.org/I4210114045","display_name":"Ovarian Cancer Canada","ror":"https://ror.org/024kejf30","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4210114045"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Alvina Nadeem","raw_affiliation_strings":["Patient Advocacy Group, Ovarian Cancer Canada, Toronto, ON M2P 2A9, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Patient Advocacy Group, Ovarian Cancer Canada, Toronto, ON M2P 2A9, Canada","institution_ids":["https://openalex.org/I4210114045"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086834252","display_name":"Christine J. Allen","orcid":"https://orcid.org/0000-0002-4916-3965","observed_orcids":["https://orcid.org/0000-0002-4916-3965"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Christine Allen","raw_affiliation_strings":["Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON M5S 3E5, Canada. Electronic address: cj.allen@utoronto.ca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON M5S 3E5, Canada. Electronic address: cj.allen@utoronto.ca","institution_ids":["https://openalex.org/I185261750"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5035592184","https://openalex.org/A5086834252"],"corresponding_institution_ids":["https://openalex.org/I185261750"],"apc_list":{"value":4440,"currency":"USD","value_usd":4440},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"396","issue":null,"first_page":"115038","last_page":"115038"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T13202","display_name":"Pharmacology and Nanomedicine Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pegylated-liposomal-doxorubicin","display_name":"pegylated liposomal doxorubicin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/nanomedicine","display_name":"nanomedicine","score":0.9520000219345093},{"id":"https://openalex.org/keywords/drug-delivery","display_name":"drug delivery","score":0.5379999876022339},{"id":"https://openalex.org/keywords/anthracycline-toxicity","display_name":"anthracycline toxicity","score":0.7319999933242798},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.7379999756813049},{"id":"https://openalex.org/keywords/time-toxicity","display_name":"time toxicity","score":0.7670000195503235},{"id":"https://openalex.org/keywords/patient-centered-outcomes","display_name":"patient-centered outcomes","score":0.9229999780654907},{"id":"https://openalex.org/keywords/translational-gap","display_name":"translational gap","score":0.7049999833106995},{"id":"https://openalex.org/keywords/reimbursement","display_name":"reimbursement","score":0.7570000290870667},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.8059999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6252999901771545},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.5983999967575073},{"id":"https://openalex.org/C12713177","wikidata":"https://www.wikidata.org/wiki/Q1900281","display_name":"Perspective (graphical)","level":2,"score":0.5774000287055969},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5145000219345093},{"id":"https://openalex.org/C185154212","wikidata":"https://www.wikidata.org/wiki/Q410454","display_name":"Liposome","level":2,"score":0.46219998598098755},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.33379998803138733},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3082999885082245},{"id":"https://openalex.org/C2984430287","wikidata":"https://www.wikidata.org/wiki/Q186249","display_name":"Pharmaceutical technology","level":2,"score":0.2827000021934509},{"id":"https://openalex.org/C3018146709","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Anticancer drug","level":3,"score":0.2651999890804291},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.2639999985694885},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2538999915122986}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000903","descriptor_name":"Antibiotics, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D050997","descriptor_name":"Nanomedicine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.jconrel.2026.115038","doi":"https://doi.org/10.1016/j.jconrel.2026.115038","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jconrel.2026.115038","pdf_url":null,"source":{"id":"https://openalex.org/S161954266","display_name":"Journal of Controlled Release","issn_l":"0168-3659","issn":["0168-3659","1873-4995"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Controlled Release","raw_type":"journal-article"},{"id":"pmid:42167367","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42167367","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of controlled release : official journal of the Controlled Release Society","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F1359353005","display_name":"NanoMedicines Innovation Network","ror":"https://ror.org/038rwe723"},{"id":"https://openalex.org/F4320334506","display_name":"Canadian Institutes of Health Research","ror":"https://ror.org/01gavpb45"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W1559459501","https://openalex.org/W1987862403","https://openalex.org/W1989230986","https://openalex.org/W1991106952","https://openalex.org/W2017225733","https://openalex.org/W2035342960","https://openalex.org/W2035594095","https://openalex.org/W2049567202","https://openalex.org/W2056768996","https://openalex.org/W2070607082","https://openalex.org/W2074544404","https://openalex.org/W2085350222","https://openalex.org/W2087414776","https://openalex.org/W2094448828","https://openalex.org/W2106810178","https://openalex.org/W2111922520","https://openalex.org/W2120984606","https://openalex.org/W2130429074","https://openalex.org/W2203091949","https://openalex.org/W2340906166","https://openalex.org/W2344644350","https://openalex.org/W2883399820","https://openalex.org/W2890167612","https://openalex.org/W3035335179","https://openalex.org/W3176370909","https://openalex.org/W3198884354","https://openalex.org/W4293537624","https://openalex.org/W4307560842","https://openalex.org/W4323352443","https://openalex.org/W4384922598","https://openalex.org/W4398143194","https://openalex.org/W4400477212","https://openalex.org/W4400968014","https://openalex.org/W4403751468","https://openalex.org/W4409386821","https://openalex.org/W4413810973"],"related_works":["https://openalex.org/W2541390219","https://openalex.org/W4406210585","https://openalex.org/W3177451573","https://openalex.org/W4409386821","https://openalex.org/W1993562925","https://openalex.org/W4403809914","https://openalex.org/W2020670695","https://openalex.org/W7160895379","https://openalex.org/W1744054130","https://openalex.org/W2500140805"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-05-21T00:00:00"}